NRXP supply chain intelligence for NRx Pharmaceuticals, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
NRx Pharmaceuticals, Inc. (NRXP) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| BTIG-LLC | BTIG-LLC | 92% | Underwriting Agreement On June 3, 2026, NRx Pharmaceuticals, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with BTIG, LLC, as representative of the se… |
| ALCAMI | ALCAMI | 90% | In December 2022, as part of our agreement with Relief Therapeutics we transferred all manufacturing rights and know-how that we acquired for ZYESAMI (aviptadil) to Relief, including our collaboratio… |
| NEPHRON-PHARMACEUTICALS | NEPHRON-PHARMACEUTICALS | 90% | In December 2022, as part of our agreement with Relief Therapeutics we transferred all manufacturing rights and know-how that we acquired for ZYESAMI (aviptadil) to Relief, including our collaboratio… |
| POLYPEPTIDE-GROUP | POLYPEPTIDE-GROUP | 90% | In December 2022, as part of our agreement with Relief Therapeutics we transferred all manufacturing rights and know-how that we acquired for ZYESAMI (aviptadil) to Relief, including our collaboratio… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from NRXP graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from NRXP graph: Reciprocal relationship from JNJ grap… |
| JNJ | Johnson & Johnson | 72% | alty pharmaceutical and biotechnology companies as well as academic and research institutions. We compete in an industry that is characterized by: (i) rapid technological change, (ii) evolving indust… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from NRXP graph: icinal use, and may not be marketed or sold in the U.S. A pharmaceutical product may be listed as Schedule II, III, … |
| ORANY | ORANY | 72% | icinal use, and may not be marketed or sold in the U.S. A pharmaceutical product may be listed as Schedule II, III, IV or V, with Schedule II substances considered to present the highest risk of abus… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| COMMERCIAL-INSURERS | COMMERCIAL-INSURERS | 90% | The Company receives payments from the following sources: (i) commercial insurers |
| INDIVIDUAL-PATIENTS-AND-CLIENTS | INDIVIDUAL-PATIENTS-AND-CLIENTS | 90% | (iv) individual patients and clients |
| MEDICAID-AND-RELATED-PROGRAMS | MEDICAID-AND-RELATED-PROGRAMS | 90% | (iii) state governments under Medicaid and related programs |
| NEPHRON-PHARMACEUTICALS | NEPHRON-PHARMACEUTICALS | 90% | In 2023, the Company entered into a development and manufacturing agreement with Nephron Pharmaceuticals, Inc. for the manufacture of ketamine HCl (NRX-100, HTX-100) that the Company intends to distr… |
| JNJ | Johnson & Johnson | 72% | Reciprocal relationship from JNJ graph: Reciprocal relationship from NRXP graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from NRXP graph: Reciprocal relationship from JNJ grap… |
| JNJ | Johnson & Johnson | 72% | alty pharmaceutical and biotechnology companies as well as academic and research institutions. We compete in an industry that is characterized by: (i) rapid technological change, (ii) evolving indust… |
| ORANY | ORANY | 72% | Part D plans include both standalone prescription drug benefit plans and prescription drug coverage as a supplement to Medicare Advantage plans. Unlike Medicare Part A and B, Part D coverage is not s… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from NRXP graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from NRXP graph: Reciprocal relationship from ORAN… |
| APKARIAN-TECHNOLOGIES-LLC | APKARIAN-TECHNOLOGIES-LLC | 62% | nd liability due to Alvogen was $ 5.5 million, which represents a total of $ 4.8 million of all payments made by Alvogen through December 31, 2025 along with the $ 0.7 million of accrued interests, a… |
| DURA-PROPERTIES-LLC | DURA-PROPERTIES-LLC | 62% | ther relevant factors. Contractual adjustments and discounts are based on contractual agreements with commercial insurance and Medicare, discount policies, and historical experience. Implicit price c… |
| GLYTECH-LLC | GLYTECH-LLC | 62% | ship 311 Trade name 673 Goodwill 1,793 Total assets acquired 4,017 Less: liabilities assumed ( 495 ) Net assets acquired $ 3,522 Certain adjustments of approximately $ 0.1 million to the purchase pri… |
| KADIMA-HOLDINGS | KADIMA-HOLDINGS | 62% | nd liability due to Alvogen was $ 5.5 million, which represents a total of $ 4.8 million of all payments made by Alvogen through December 31, 2025 along with the $ 0.7 million of accrued interests, a… |
| KADIMA-MEDICAL-KADIMA-HOLDINGS-INC | KADIMA-MEDICAL-KADIMA-HOLDINGS-INC | 62% | nd liability due to Alvogen was $ 5.5 million, which represents a total of $ 4.8 million of all payments made by Alvogen through December 31, 2025 along with the $ 0.7 million of accrued interests, a… |
| NEPHRON-PHARMACEUTICALS-INC | NEPHRON-PHARMACEUTICALS-INC | 62% | Patent/Appl. No. Status/Notes USA 9,789,093 Granted Europe EP 2 670 409 Granted; validated in Switzerland, Germany, Spain, France, Great Britain, Ireland, Italy, Netherlands USA 17/502,606 Pending US… |
| POLYPEPTIDE-GROUP | POLYPEPTIDE-GROUP | 62% | Patent/Appl. No. Status/Notes USA 9,789,093 Granted Europe EP 2 670 409 Granted; validated in Switzerland, Germany, Spain, France, Great Britain, Ireland, Italy, Netherlands USA 17/502,606 Pending US… |
| STREETERVILLE-CAPITAL-LLC | STREETERVILLE-CAPITAL-LLC | 62% | nd liability due to Alvogen was $ 5.5 million, which represents a total of $ 4.8 million of all payments made by Alvogen through December 31, 2025 along with the $ 0.7 million of accrued interests, a… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| NRXP-DEBT | Debt stack $12.0M | 90% | Market cache reports total debt of $12.0M. |
| NRXP-DEBT-11371 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2025-12-31. |
| NRXP-DEBT-11370 | Warrants outstanding: 270000 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| NRXP-OWNER-B-GROUP-INC | B Group, Inc. | 90% | 13F overlay lists B Group, Inc. as top holder; 35 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| BCAX | Bicara Therapeutics Inc. | 100.00 | 2 | |
| ATON | AlphaTON Capital Corp | 100.00 | 2 | |
| SNNUF | Smith & Nephew plc | 100.00 | 2 | |
| CLGN | CollPlant Biotechnologies Ltd. | 100.00 | 2 | |
| ACIU | AC Immune SA | 100.00 | 2 | |
| AURA | Aura Biosciences, Inc. | 100.00 | 2 | |
| BNR | Burning Rock Biotech Limited | 100.00 | 2 | |
| CSTE | Caesarstone Ltd. | 100.00 | 2 | |
| ORANY | ORANGE | 100.00 | 1 | ['customer', 'supplier'] |
| ATRA | Atara Biotherapeutics, Inc. | 100.00 | 2 | |
| ADGM | Adagio Medical Holdings, Inc. | 100.00 | 2 | |
| ABBV | AbbVie Inc. | 100.00 | 2 | |
| AORT | Artivion, Inc. | 100.00 | 2 | |
| AVBP | ArriVent BioPharma, Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| BLLN | BillionToOne, Inc. | 100.00 | 2 | |
| ANIK | Anika Therapeutics, Inc. | 100.00 | 2 | |
| BNRG | Brenmiller Energy Ltd | 100.00 | 2 | |
| ALC | Alcon Inc. | 100.00 | 2 | |
| FDMT | 4D Molecular Therapeutics, Inc. | 100.00 | 2 |